Multiplex PCR Assay-Directly on Blood for Fungi: Introduction, Principle, Clinical Significance, and Keynotes

Introduction

Fungal bloodstream infections (fungemia) are life-threatening, especially in immunocompromised and oncology patients. Conventional methods like blood culture are slow, often requiring several days for growth and identification. Multiplex PCR directly on blood offers rapid, sensitive, and simultaneous detection of multiple fungal pathogens without the need for culture. This molecular approach improves diagnostic yield and facilitates timely antifungal therapy.

Principle

Multiplex PCR works by amplifying DNA fragments of several fungal species in a single reaction tube using:

• Species-specific primers targeting conserved fungal genomic regions (e.g., ITS, 18S rRNA, β-tubulin, or resistance genes).
• Simultaneous amplification of multiple targets, distinguished by product size or probe labeling.
• Direct extraction of fungal DNA from whole blood or plasma, bypassing the time-consuming culture step.
• Detection methods include gel electrophoresis, real-time PCR with fluorescent probes, or automated platforms that differentiate multiple fungi in parallel.

This allows broad coverage of pathogens, including Candida spp., Aspergillus spp., Cryptococcus spp., Fusarium, Mucorales, and emerging fungi.

Clinical Significance of Multiplex PCR Assay

1. Early Diagnosis: Provides results within hours versus days needed for culture.
2. Broad Detection: Simultaneous identification of multiple clinically relevant fungi.
3. Improved Sensitivity: Detects fungi even in culture-negative or pretreated patients.
4. Targeted Therapy: Facilitates rapid initiation or adjustment of antifungal treatment, reducing morbidity and mortality.
5. Resistance Marker Identification: Some multiplex PCR assays incorporate resistance genes (e.g., CYP51A, FKS, ERG11) to predict antifungal resistance.
6. Reduced Empiric Therapy: Minimizes unnecessary broad-spectrum antifungal use, lowering costs and toxicity.
7. Use in Oncology/Transplant Patients: Critical for high-risk groups where fungal infections progress rapidly.

Keynotes on Multiplex PCR Assay

• Direct multiplex PCR on blood bypasses the limitations of culture-based diagnostics.
• Turnaround time: <6–8 hours, compared to 2–7 days with cultures.
• Clinical relevance: Early detection improves survival in invasive candidiasis and aspergillosis.
• Limitations:
  • May detect non-viable fungi (leading to false positives).
  • Requires specialized equipment and trained personnel.
  • Sensitivity may vary depending on the fungal burden and the efficiency of DNA extraction.
• Commercial assays are available, e.g., SeptiFast, MycoReal, Fungiplex, and FilmArray, although adoption varies by region.
• Best suited for: Immunocompromised patients (oncology, hematology, ICU, transplant) where invasive fungal infections are common.

Further Readings

1. https://www.mdpi.com/2075-4418/15/8/1044
2. https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-406
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7712097/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC12026191/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3879189/
6. https://www.mdpi.com/2309-608X/5/3/86
7. https://www.mdpi.com/2309-608X/6/4/308
8. https://bsac.org.uk/wp-content/uploads/2025/05/39.pdf